COGT - CIK 0001622229
The table below shows Cogent Biosciences, Inc.'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $269.78M | $232.66M | $173.75M | $121.63M | $55.91M | $25.74M |
| SG&A | $63.58M |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $43.28M |
| $34.38M |
| $26.21M |
| $19.64M |
| $17.42M |
| Operating income | -$333.36M | -$275.94M | -$208.13M | -$147.84M | -$75.55M | -$82.20M |
| Income tax | $0.00 | - | - | - | - | - |
| Net income | -$328.94M | -$255.86M | -$192.41M | -$140.24M | -$72.27M | -$74.81M |
| EPS (diluted) | -$2.16 | -$1.94 | -$1.94 | -$1.73 | -$1.87 | - |